215 related articles for article (PubMed ID: 26510505)
1. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED.
Aragon-Ching JB
Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505
[TBL] [Abstract][Full Text] [Related]
2. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel for hormone-sensitive metastatic prostate cancer.
Baker H
Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
[No Abstract] [Full Text] [Related]
4. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
[TBL] [Abstract][Full Text] [Related]
5. CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.
Teo MY; Scher HI
Nat Rev Clin Oncol; 2015 Dec; 12(12):687-8. PubMed ID: 26552950
[No Abstract] [Full Text] [Related]
6. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
7. Mapping the course after CHAARTED.
Higano CS
Nat Rev Urol; 2015 Dec; 12(12):656-8. PubMed ID: 26526753
[No Abstract] [Full Text] [Related]
8. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
9. [Hormonal therapy for advanced prostate cancer: current status and issues].
Akakura K
Nihon Rinsho; 2016 Jan; 74(1):124-8. PubMed ID: 26793892
[TBL] [Abstract][Full Text] [Related]
10. Current treatment of advanced prostate cancer.
Ismail M; Gomella LG
Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
[TBL] [Abstract][Full Text] [Related]
11. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
Ciccarese C; Santoni M; Massari F
N Engl J Med; 2016 Jan; 374(3):286. PubMed ID: 26789884
[No Abstract] [Full Text] [Related]
12. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
Garcia JA; Sweeney C;
N Engl J Med; 2016 Jan; 374(3):287. PubMed ID: 26789883
[No Abstract] [Full Text] [Related]
13. Adding chemotherapy to hormonal therapy prolongs survival in metastatic prostate cancer, study finds.
Mayor S
BMJ; 2015 Aug; 351():h4253. PubMed ID: 26251343
[No Abstract] [Full Text] [Related]
14. Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Shahani R; Fleshner NE; Zlotta AR
Discov Med; 2007 Aug; 7(39):118-24. PubMed ID: 18093474
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
17. Will chemotherapy change the management of prostate cancer?
Gilson C; Sydes MR; Chowdhury S
BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
[No Abstract] [Full Text] [Related]
18. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Taneja SS
J Urol; 2016 Jan; 195(1):94. PubMed ID: 26699961
[No Abstract] [Full Text] [Related]
19. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
20. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
Pitts WR
BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
